Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 March 2021

Message from Prof Francis Petersen, Rector and Vice-Chancellor: 5 March 2021

Dear Senior Undergraduate Students

We are well into the first part of 2021 with the University of the Free State’s (UFS) academic programme that commenced on 1 March 2021.

This communication aims to provide our senior undergraduate students with information and some clarity on how the university is approaching the start of its academic programme and the progress that has been made. The COVID-19 pandemic has posed many challenges to universities across the country; for instance, to find innovative ways of completing the 2020 academic year without leaving any student behind and, at the same time, keeping safety, health, and well-being a top priority.

The pandemic provided ample opportunities to embrace technology and introduce new innovative learning and teaching approaches in 2020, as well as a first-ever online registration process for all our students in 2021. The higher-education landscape is now being reshaped by rapid advances in technology, and this will require continued commitment from all of us to reimage communities that were unimaginable just a decade ago.

With this in mind, one needs to emphasise that any substantial change-management process will pose challenges. To date, 64% of our students who have registered, have done so online. This is a sharp increase from the comparable 20% of last year. I would like to take this opportunity to thank our students and staff for embracing this substantial change in our processes.

However, the university is aware that some of our students find it difficult to register for several reasons, and that this is creating unprecedented anxiety levels among staff and students. It is therefore very important that we identify the underlying blockages and find amicable solutions to ensure that those students who have not yet registered, can do so speedily. Furthermore, it is crucial that the digital skills of our students are developed, as this will be the way in which the university will approach the registration process in the future.

The university’s blended learning programme for 2021 allows for 34% of students to return during the first semester. Although our country is currently on Level 1 of the national lockdown, the percentage of students who return is not linked to the lockdown level, but to the university’s teaching and learning approach and the institution's infrastructure capacity to adhere to physical distancing protocols.

I am aware of the recent comment made by Dr Zweli Mkhize regarding a third wave of COVID-19 post-Easter, as the country continues to roll out its vaccination strategy. Easter is typically a period of family gatherings and the university holidays also follow the Easter weekend. This is yet another reason why the university is exercising caution in its return-to-campus strategy.

To ensure that senior undergraduate students register successfully and can continue with their studies, the following measures have been put into place:

1. The online registration process is extended until Friday 12 March 2021 to allow students who have not yet registered to do so.

2. Classes for selected senior undergraduate students that commenced on or before 1 March 2021, will continue. However, students whose registration has been delayed due to the online registration process, will be supported through a differentiated commencement of classes allowing for a catch-up plan, thus avoiding any student being left behind. Faculties will communicate to these students when online classes will be starting.

3. Additional capacity will be provided to support faculties and campuses in order to expedite the registration process. The university management is aware of the high volumes of enquiries and calls received from students, and this intervention will assist with the turnaround time. In extreme circumstances, students who are identified as vulnerable and are still experiencing challenges with registering, will be requested to do so on campus where they will be assisted in a central venue.

These measures have been put in place for the benefit of our students and to ensure that we can all complete the 2021 academic year successfully.

It is understandable that those students who will not return to the campuses will miss campus life and would like their student life to return to the way it was. However, access to the campuses remains restricted to only registered students for face-to-face teaching and identified postgraduate students in possession of valid 2021 campus-access permits. Permits are being issued centrally and are valid for the period that a student is expected to be on campus. This measure remains in place to ensure compliance with the national regulations and to mitigate the risk of spreading COVID-19.

The dedication and commitment of staff are commendable; they are working tirelessly to support our students during this time, and I thank them for their supportive spirit. In the end, our collective goal is to ensure that our students succeed this year, and that no student is left behind.

Remember that the pandemic continues to test every aspect of society, and although the infection rate is slowly decreasing and the vaccine is rolled out across the country, we must not underestimate the impact that the pandemic still has on local and global communities. Take care of yourselves and those around you and comply with the national guidelines and regulations.

I would like to encourage you to stay in touch with the university. Visit the UFS website and social-media platforms for regular updates and consult your ufs4life email for communication from the university.

I wish you all the best with your studies during the first term and hope to see you on our campuses soon.

Download the letter (pdf)

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept